Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 274931


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • ribonucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 274931

License Grant
The Israeli Licensor hereby grants to the Israeli Licensee the sole and exclusive worldwide license, even as to Licensor, under its part in the Research Results and the and Patent Rights, including the right to grant sublicenses on the terms set forth herein, to research, develop, use, import, offer for sale, market, commercialize, manufacture, distribute and sell the Products in the Territory.
License Property
Patent Rights shall mean United States and foreign patents and patent applications (which shall be deemed to include certificates of invention and applications for certificates of invention) which as of the Effective Date or at any time during the term of this Agreement relate in any way to Research ResultsResearch Results shall mean any and all microRNAs expression profiling data measured on the Materials, and its analysis pertaining to potential diagnostic application, as determined in the course of the performance of the Research Project.

Products – any products developed and/or manufactured based upon and/or in connection with the Patent Rights.

Licensee has developed confidential and proprietary technology relating to microRNA sequences including an algorithm for the prediction of microRNAs, techniques for validation of predicted microRNAs on a given material, microRNA expression profiling technology, analysis algorithms for the detection of biomarkers based on microRNA expression profiling and techniques for establishing the relationships between microRNAs and diseases and has identified a large number of microRNA sequences using certain of its proprietary technology and/or proprietary materials.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 362451

License Grant
Licensor hereby grants French Licensee the nonexclusive, nontransferable right, exercisable in accordance with this Agreement to obtain the nonexclusive license set forth under the terms and conditions set forth in this Agreement to conduct Research on microRNA Compounds, including a technology sharing from Licensor; and (ii) an exclusive license to Develop and Commercialize a limited number of microRNA Compounds as Option Products.

Commercial License Licensor will grant to Licensee a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses as set forth, under the Licensor Platform Technology to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import Option Compounds and Option Products. The licenses granted to Licensee are fully sublicensable to any Affiliate of Licensee, and only sublicensable to a Third Party in connection with a sublicense of an Option Compound or Option Product for the continued Research, Development and Commercialization of such Option Compound or Option Product in accordance with the terms of this Agreement.

License Property
microRNA Compound means a compound consisting of (a) a microRNA Antagonist, or (b) a microRNA Mimic.

microRNA Antagonist means a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to interfere with or inhibit a particular microRNA.

microRNA Mimic means a double-stranded or single-stranded oligonucleotide or analog thereof with a substantially similar base composition as a particular microRNA and which is designed to mimic the activity of such microRNA.

Option Compound means either (i) with respect to Option Targets for which Licensee has selected a microRNA Antagonist under Section 3.1 above, any microRNA Antagonist discovered by Licensee or its Affiliates that modulates the expression of such Option Target where its primary mechanism of action is through its hybridization to such Option Target, or (ii) with respect to Option Targets for which Licensee has selected a microRNA Mimic under Section 3.1 above, a microRNA Mimic discovered by Licensee or its Affiliates with a substantially similar base composition as the applicable Option Target and which is designed to mimic the activity of such Option Target.

Licensor Platform Technology Patents means, (A) all Patents Controlled by Licensor on the Effective Date and listed in Agreement and (B) all Patents Controlled by Licensor during the IP Period that claim (a) microRNA Compounds in general, (b) chemistry or delivery technology useful technology useful in connection with microRNA Compounds, (c) general mechanisms of action by which a microRNA Compound modulates microRNAs, or (d) general methods of treating or preventing an Indication by modulating one or more microRNAs; provided, however, that in each case, Licensor Platform Technology Patents do not include (1) any Patents Controlled by Licensor or its Affiliates to the extent that such Patents claim (a) the sequence or a portion thereof corresponding to a specific microRNA sequence or a portion thereof, (b) the specific composition of matter of any microRNA Compound, (c) methods of using as a therapeutic any microRNA Compound; (2) the Tuschl 3 Patents; and (3) the Rockefeller Patents.

Field of Use
The collaboration and license agreement which we subsequently amended, restated and superseded in July 2012 is to develop and commercialize licensed compounds targeting four microRNA alliance targets initially focused in the field of fibrosis.  The July 2012 amended and restated agreement expanded the alliance to include potential microRNA therapeutics in oncology.
Field of use is for therapeutic applications relating to orphan diseases and oncology targets.

IPSCIO Record ID: 263910

License Grant
The University grants the Israeli Licensor a co-exclusive, world-wide license to make, have made, use, have used, import, sell, have sold, and offer for sale Licensed Products in the Field of Use during the Term.
License Property
The technology relates to microRNA sequences.  The patents are for Anti Micro-RNA Oligonucleotide Molecules;  Pancreatic Islet MicroRNAs and Methods for Inhibiting Same;   DNA Virus MicroRNAs and Methods for Inhibiting Same; and,  Human MicroRNAs and Methods for Inhibiting Same.
Field of Use
The term Field of Use means human and animal therapeutics.

MicroRNAs have been shown to hold tremendous potential as a new class of prospective drug targets with significant therapeutic opportunity.

MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers

Licensee's lead therapeutic development program for liver cancer (hepatocellular carcinoma or HCC) has so far identified four microRNAs that when inhibited in vitro lead to a decrease in liver cancer cell proliferation.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.